Hot Stocks Soaring: New orders, strong earnings, and cancer research wins

*together with Theo Trade & Paladin Power

Good day, 360!

Here are some of our top movers today. And please join the dynamic duo - Jeff Bishop & Don Kaufman - TODAY at 1pm EST for a Special Session on Earnings Trading:

FOCUS LIST🔎

STSS - Up over 33% in the pre market after securing $400K initial purchase order from U.S. leader in IV flushing solutions as part of $50 million SoloGard supply agreement 

PPBT - Up over 10% in pre after announcing final data from Phase 2 Study of CM24 in Pancreatic Cancer patients at AACR 2025 annual meeting: improved outcomes and significant efficacy in biomarker-enriched subgroups

FRSH - Up over 10% in pre after announcing better than expected Q1 2025 financial results

HOTLIST🔥

STSS - Up over 33% in the pre market after securing $400K initial purchase order from U.S. leader in IV flushing solutions as part of $50 million SoloGard supply agreement  

Sharps Technology Inc. (STSS) is a medical device and pharmaceutical packaging company that engages in the design, research and development, manufacturing, and commercialization of safety syringe products in the United States.

In the pre-market this morning, the company announced the receipt of a $400,000 purchase order from a U.S. leader in IV flushing solutions. This marks the first order under the previously announced $50 million supply agreement from July 2024.

The milestone order marks first commercial revenue for Sharps Technology under multi-year, 500-million syringe agreement

Investments in best-in-class manufacturing equipment position Sharps to offer differentiated high-volume syringe production to meet long-term contract demand.

Shares of STSS traded up over 33% in the pre-market in reaction to the news.

The first target for bulls is the pre-market high at $7.90. Beyond that, $9, $10 and $11 come into play.

Below $7.90, targets to the downside are $6.50, $6.20, $5.60 and then a gap fill at $5.

PPBT - Up over 10% in pre after announcing final data from Phase 2 Study of CM24 in Pancreatic Cancer patients at AACR 2025 annual meeting: improved outcomes and significant efficacy in biomarker-enriched subgroups

Purple Biotech Ltd. (PPBT) is a clinical-stage company that focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States.

In the pre-market this morning, the company announced that a poster presentation titled “Final analysis of the randomized Phase 2 cohort of CM24 with nivolumab and chemotherapy in pancreatic cancer & potential serum biomarkers” is being presented during the session “Liquid Biopsy: Circulating Nucleic Acids 4 / Predictive Biomarkers 1” at the Annual Meeting of the American Association of Cancer Research (AACR 2025) on Wednesday, April 30, 2025.

Highlights include:

• 78% reduction in risk of death and 81% reduction in risk of progression or death in defined pretreatment ranges of serum or tumor CEACAM1 subgroup

• 61% reduction is risk of death and 72% reduction in risk of progression or death in defined pretreatment ranges of serum CEACAM1 or myeloperoxidase (MPO) subgroup

• 90% reduction is risk of death and 81% reduction in risk of progression or death in high tumor CEACAM1 and low PD-L1 combined positive score (CPS) subgroup

Shares of PPBT traded up over 10% in the pre-market in reaction to the news.

The $2.70 area acted as support in the pre-market and will be an important level to watch.

Above it, targets to the upside are $2.90, $3, $3.15 and then the pre-market high at $3.30. Beyond that, $3.50 and $3.85 come into play.

Below $2.70, targets to the downside are $2.60 and then a gap fill at $2.53 with $2.37 below that.

FRSH - Up over 10% in pre after announcing better than expected Q1 2025 financial results

Freshworks Inc. (FRSH) is a software development company that provides software-as-a-service products in North America, Europe, the Middle East, Africa, Asia Pacific, and internationally.

In the after-hours yesterday, the company announced financial results for its first quarter ended March 31, 2025.

Highlights include:

• Revenue: Total revenue was $196.3 million, representing growth of 19% compared to total revenue of $165.1 million in the first quarter of 2024, and 19% adjusting for constant currency.
  

• GAAP (Loss) from Operations: GAAP (loss) from operations was $(10.4) million, compared to $(32.2) million in the first quarter of 2024.
  

• Non-GAAP Income from Operations: Non-GAAP income from operations was $46.4 million, compared to $21.8 million in the first quarter of 2024.

• Adjusted Free Cash Flow: Adjusted free cash flow was $55.4 million, compared to $38.7 million in the first quarter of 2024.
  

• Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents, and marketable securities were $1.0 billion as of March 31, 2025.

Shares of FRSH traded up over 10% in the pre-market in reaction to the news.

The first target for bulls is the pre-market high at $16.29. Beyond that, $16.60, $17 and $17.69 come into play.

Below $16.29, targets to the downside are $15.65, $15.50 and then a gap fill at $14.34.

MARKET NEWS 📰

Don't miss out on our MOBILE ALERTS!  Some of these alerts have rocketed 🚀past the MOON 🌝.  Text “RAGE” to 1-(888) 487-1534 📲.

*Disclosure: By texting “RAGE” to 1-(888) 487-1534, you agree to receive promotional messages sent via an autodialer. You also agree to the terms of service and privacy policy. This agreement isn’t a condition of any purchase. Message frequency varies. Message and data rates may apply. Reply STOP to opt out; HELP for more information.